Robert Elfont, MD, PhD, is Aimmune’s Chief Medical Officer. Dr. Elfont founded the specialty consulting firm, Strategic Clinical Development, LLC, in 2009. He has served as CMO for several biotech companies including PhotoThera and Avigen. Before moving to the biotech sector, Dr. Elfont held senior medical director positions at Roche, Pfizer and Teva Neuroscience. While at Teva, Dr. Elfont worked in the field of orally induced immune tolerance. Dr. Elfont was also an assistant professor of neurology at Johns Hopkins University School of Medicine and Drexel University College of Medicine. - See more at: http://www.aimmune.com/about/team/#sthash.ifEAHcko.dpuf
His research activities focused on immune cell trafficking. Dr. Elfont completed a neurology residency and fellowship in neuroimmunology and neurovirology at Johns Hopkins. He earned his MD and PhD from the University of Rochester and received additional post-graduate training at the University of Cambridge.